

**Fall Cornea Update - Feat. the Peter R. Laibson, MD Endowed Lecture (10/29/2022 @ 8 a.m. ET)**

**Saturday, October 29, 2022**

*Wills Eye Auditorium*

**[Conference Description:](https://attendee.gotowebinar.com/register/6424566712883937296%22%20GoToWebinar%20LivestreamWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[GoToWebinar Livestream](https://attendee.gotowebinar.com/register/6424566712883937296%22%20GoToWebinar%20LivestreamWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/6424566712883937296%22%20GoToWebinar%20LivestreamWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

3 Assess the role of new technologies in the evaluation and treatment of eye diseases.

4 Describe factors that impact the effective delivery of the highest quality eye care for the public.

5 Identify clinical, scientific, and ethical issues confronting the profession.

6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Guillermo Amescua, MD | Faculty | Royalties or Patent Beneficiary-Kala Pharmaceuticals|Consulting Fee-Sun Pharmaceutical Industries (Relationship has ended) - 10/10/2022 |
| John C Anhalt, MD | Faculty | Nothing to disclose - 05/02/2022 |
| Brandon D. Ayres, MD | Faculty | Consulting Fee-Alcon|Consulting Fee-Allergan|Consulting Fee-Bausch + Lomb|Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-Novartis|Consulting Fee-Dompé  - 10/27/2022 |
| Vatinee Bunya, MD | Faculty | Nothing to disclose - 10/12/2022 |
| Brad H Feldman, MD | Faculty | Nothing to disclose - 10/13/2022 |
| Brenton D. Finklea, MD | Faculty | Honoraria-CorneaGen (Relationship has ended) - 10/10/2022 |
| Kristin M. Hammersmith, MD | Faculty | Nothing to disclose - 10/27/2022 |
| Sadeer B. Hannush, MD | Faculty | Consulting Fee-Kowa, Inc - 10/27/2022 |
| Aditya Kanesa-thasan, MD | Faculty | Nothing to disclose - 10/26/2022 |
| Beeran Meghpara, MD | Faculty | Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-Glaukos Corporation|Consulting Fee-Johnson & Johnson|Consulting Fee-Santen Pharmaceuticals|Consulting Fee-Kala Pharmaceuticals|Consulting Fee-OCULUS Surgical, Inc.|Consulting Fee-Allergan|Consulting Fee-Sight Sciences|Consulting Fee-CorneaGen|Consulting Fee-Dompé |Consulting Fee-Zeiss - 10/09/2022 |
| Parveen K. Nagra, MD | Faculty | Nothing to disclose - 10/25/2022 |
| Ravi Patel, MD, MBA | Faculty | Speakers Bureau-Allergan|Consulting Fee-Johnson & Johnson|Grant or research support-Ocular Therapeutix|Consulting Fee-Kala Pharmaceuticals (Relationship has ended) - 10/12/2022 |
| Michael Pro, MD | Faculty | Advisor-New World Medical - 10/27/2022 |
| Irving M. Raber, MD | Faculty | Nothing to disclose - 10/11/2022 |
| Christopher J. Rapuano, MD | Faculty | Consulting Fee-Bio-Tissue|Consulting Fee-Dompé |Consulting Fee-Glaukos Corporation|Consulting Fee-Oyster Point Pharmaceuticals|Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-TearLab|Honoraria-Dompé  - 02/16/2022 |
| Zeba A. Syed, MD | Faculty | Speakers Bureau-Bio-Tissue|Grant or research support-Dompé |Grant or research support-Glaukos Corporation - 10/14/2022 |
| Cindy Zheng , MD | Faculty | Nothing to disclose - 10/25/2022 |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds-Merck - 06/07/2022 |

